2022H1GSK performance: the structural adjustment has achieved initial results, the performance of star products has reached a new high, and the full-year forecast has been raised
Time of Update: 2022-08-15
Among them, the anti-PD-1 antibody Jemperli (dostarlimab, dotalimab) developed by the company was granted accelerated approval by the FDA in April 2021 for the treatment of patients with disease progression after receiving platinum-containing chemotherapy and carrying mismatch repair deficiency (dMMR) DNA repair abnormalities.
Express prolongs the life of patients with advanced breast cancer by nearly 16 months, and the long-term clinical results of Novartis CDK4/6 inhibitor are positive
Time of Update: 2022-05-27
▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced or metastatic breast cancer In the phase 3 clinical trial of fulvestrant, the overall survival of patients was extended by nearly 16 months .
Under the normal situation that pharmaceutical companies have joined forces, the amount of cooperation is continuing to grow
Time of Update: 2022-05-08
[Pharmaceutical Network Industry News] In recent years, affected by the changes in the pharmaceutical industry, in order to respond to more and more market challenges and accelerate the development and commercialization of innovative drugs, the cooperation between pharmaceutical companies is becoming more and more frequent .
Clin Cancer Res: Efficacy of temozolomide combined with radiotherapy vs radiotherapy alone in IDH wild-type glioblastoma
Time of Update: 2022-04-22
Does adjuvant radiotherapy combined with temozolomide improve outcomes in patients with anaplastic astrocytoma without IDH1/2 mutations with molecular features of glioblastomaThe CATNON trial was a randomized phase 3 study to investigate the effect of adjunctive or concurrent use of temozolomide during radiotherapy in patients with anaplastic astrocytoma .
Cardiovasc Diabetol: GLP-1 receptor agonist VS basal insulin-for comparison of cardiovascular outcomes after conventional treatment of type 2 diabetes
Time of Update: 2021-12-02
Diabetes Metformin management consensus researchers want to verify, whether to start the GLP-1RA in routine clinical practice in T2D patients showed better heart vascular outcomes, and to this end a regional retrospective study .
The first-line clinical trial of the first-line treatment of advanced HCC in the treatment of advanced HCC with ALK-1 monoclonal antibody combined with O-drug of Kaixing Pharmaceutical was approved
Time of Update: 2021-10-21
On October 11, Kaifeng Pharmaceutical announced that the clinical trial of ALK-1 monoclonal antibody (GT90001C) combined with Nivolumab has been approved by the China National Medical Products Administration on October 9 for use in advanced hepatocytes without systemic treatment.
New hope: immunotherapy helps preserve muscular layer of bladder invasive bladder cancer
Time of Update: 2021-10-02
The researchers conducted a phase II study to explore the efficacy and safety of pembrolizumab + gemcitabine (Gem) + simultaneous hypofractionated radiotherapy (RT) for muscularis sparing invasive bladder cancer (MIBC) .
[Early bird deadline this Friday] IGC’s full lineup of agendas will be launched, and the world’s top experts will gather in the capital of Golden Autumn to explore the new future of immune gene
Time of Update: 2021-07-30
As the annual brand event in the field of immune gene and cell therapy, IGC 2021 5th China International Immune Gene and Cell Therapy Forum will be grandly opened in Beijing on September 1-2 . Profes
Johnson & Johnson abandons Erleada, Zytiga prostate cancer combination therapy regulatory application
Time of Update: 2021-05-23
CompilationFan DongdongAfter failing to reach the secondary endpoint of the key Phase III trial, Johnson & Johnson said it will not seek a regulatory application for the prostate cancer drug combination Erleada and Zytiga in the future.
What are the new targets and new therapies for precise treatment of advanced gastric cancer
Time of Update: 2021-04-19
Some of these targeted therapies have obtained positive results in clinical trials and are expected to further improve the pattern of precision treatment for patients with gastric cancer.
CHMP recommends approval of Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of recurrent multiple myeloma
Time of Update: 2021-03-20
Recently, the European Medicines Management Agency (EMA) Committee for Medicinal suggested use (CHMP) approved Sarclisa (isatuximab) and carfilzomib and dexamethasone (Kd) used in combination relapsed multiple myeloma (MM), these patients previously Have received at least one therapy.
Genetic studies provide the most comprehensive map of breast cancer risk to date
Time of Update: 2021-02-19
major international study on breast cancer genetics has identified more than 350 DNA "errors" that increase an individual's risk of developing the disease.
Tumor immunotherapy upgrade! AstraZenecom's New Dosing Scheme (1500mg once every 4 weeks) has been approved in the EU
Time of Update: 2021-01-27
January 15, 2021 // -- AstraZeneca recently announced that the European Commission (EC) has approved a new dose option for anti-PD-L1 therapy Imfinzi (Infinfan, generic name: durvalumab, dovalyu monoanti) every 4 Mondays A secondary fixed dose of 1500 mg for approved non-small cell lung cancer (NSCLC) adaptation, specifically for adult patients with local late stage or non-removable NSCNC after receiving platinum-containing chemotherapy (CRT), tumor expression PD-L1 (≥1% tumor cells).
From "intentional avoidance" to "research and development hotspot" co-price inhibitors how to innovate the development of small molecule drugs
Time of Update: 2021-01-21
Although several significant drugs in the history of human medicine have included co-price mechanisms, drug developers have long deliberately avoided compounds that can be combined with target co-prices when selecting target inhibitors.
U.S. FDA Grants Phosphate Inositol-3-Kinase (PI3K) Inhibitor umbralisib (TGR-1202) Orphan Drug Qualification
Time of Update: 2020-06-10
recently, TG (http:// announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has granted the phosphate inositol-3-kinase (PI3K) inhibitor umbralisib (PiGR-1202) orphan